Naive CD4+ T cells differentiate into effector subsets (TH1, TH2, TH17, TREG) through coordinated programmes driven by T cell receptor (TCR) engagement, co-stimulation, and cytokine signalling. These differentiation programmes require adaptation of stress-responsive pathways, including the unfolded protein response (UPR) and the oxidative stress response (OSR), to meet the distinct physiological demands of each subset. The study explores whether pharmacologic modulation of these stress-responsive pathways can be used to selectively remodel CD4+ T cell subset differentiation.
The compound AA147 is characterized as a metabolically activated proteostasis regulator. Prior work identified AA147 as an inducer of the ATF6 signalling arm of the UPR and, in certain cell types, an activator of the NRF2-regulated arm of the OSR. The present work builds on those observations to evaluate AA147's influence on CD4+ T cell differentiation, focusing on functional and transcriptional consequences during the differentiation process.
Treatment with AA147 selectively reduced differentiation of pro-inflammatory TH17 cells from naive CD4+ T cells. This selective effect was linked to AA147-promoted degradation of the TH17 lineage-specifying transcription factor RORgammat. Importantly, the authors report that AA147 did not impact the core transcription factors that define other CD4+ T cell subsets, indicating a degree of selectivity for TH17 identity.
The finding that AA147 reduces RORgammat levels provides a direct molecular mechanism by which TH17 differentiation is impaired. The source reports that this degradation is central to the compound's ability to reduce the emergence of TH17 cells during differentiation.
The AA147-dependent reduction in TH17 differentiation was found to be independent of activation of the ATF6 arm of the UPR. Instead, the effect involves activation of NRF2, a master regulator of cellular antioxidant responses. Activation of NRF2 by AA147 leads to reduced intracellular reactive oxygen species (ROS), and the lowered ROS environment is proposed to hinder TH17 cell differentiation.
Thus, the mechanism described links AA147 metabolic activation to NRF2-driven antioxidant programmes that alter the redox state of differentiating T cells, which in turn impacts lineage choice toward diminished TH17 development.
Although AA147 can induce ATF6 in some contexts, the reported reduction in TH17 differentiation in this study occurs without dependence on ATF6 activation. Beyond effects on RORgammat, AA147 also decreased expression of the TCR-responsive transcription factor IRF4. Because IRF4 is involved in TCR-driven responses and effector programmes, its downregulation by AA147 contributed to suppressed production of selected effector cytokines across effector T cell subsets.
Therefore, AA147 appears to reshape T cell functions through at least two routes: a selective, NRF2-linked decrease in TH17-defining RORgammat and a broader suppression of IRF4-associated effector cytokine production that affects multiple effector subsets.
The results support the concept that targeting stress-responsive signalling pathways with metabolically activated proteostasis regulators such as AA147 can selectively modulate T cell subset identity—most notably by reducing TH17 differentiation—while also broadly dampening certain effector cytokine responses. These dual actions occur through both NRF2-dependent and NRF2-independent mechanisms during T cell differentiation, offering multiple levers by which T cell function can be reshaped pharmacologically.
As reported in the source, the work is presented as a preprint and has not undergone peer review. The source does not provide clinical data, in vivo efficacy, dosing, toxicity, or translational development details in the abstract; those specifics were not reported in the provided source text.
The preprint discloses a competing interest: RLW is a shareholder and scientific advisory board member of Protego Biopharma, which has licensed proteostasis regulators including AA147 for commercial development. Other authors declared no conflicts. Funding sources listed in the source include NIH grants and several foundations. The manuscript is available under a CC-BY 4.0 license and is a bioRxiv preprint, indicating it is not yet peer reviewed.